Literature DB >> 25779381

Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America.

David Wofsy1, Betty Diamond, Frédéric A Houssiau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25779381      PMCID： PMC4523131          DOI： 10.1002/art.39067

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  10 in total

1.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

Authors:  Marilyn Thien; Tri Giang Phan; Sandra Gardam; Michelle Amesbury; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

2.  Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.

Authors: 
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

3.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

4.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido Ed; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2002-08

5.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

Authors:  H A Austin; J H Klippel; J E Balow; N G le Riche; A D Steinberg; P H Plotz; J L Decker
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

6.  B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Authors:  G Cambridge; D A Isenberg; J C W Edwards; M J Leandro; T-S Migone; M Teodorescu; W Stohl
Journal:  Ann Rheum Dis       Date:  2007-10-25       Impact factor: 19.103

7.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

8.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Authors:  F A Houssiau; C Vasconcelos; D D'Cruz; G D Sebastiani; E de Ramon Garrido; M G Danieli; D Abramovicz; D Blockmans; A Cauli; H Direskeneli; M Galeazzi; A Gül; Y Levy; P Petera; R Popovic; R Petrovic; R A Sinico; R Cattaneo; J Font; G Depresseux; J-P Cosyns; R Cervera
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  A checkpoint for autoreactivity in human IgM+ memory B cell development.

Authors:  Makoto Tsuiji; Sergey Yurasov; Klara Velinzon; Saskia Thomas; Michel C Nussenzweig; Hedda Wardemann
Journal:  J Exp Med       Date:  2006-01-30       Impact factor: 14.307

10.  Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice.

Authors:  Daisuke Kawabata; Jeganathan Venkatesh; Meera Ramanujam; Anne Davidson; Christine M Grimaldi; Betty Diamond
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240
  10 in total
  7 in total

Review 1.  Lupus Nephritis: A Different Disease in European Patients?

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Kidney Dis (Basel)       Date:  2015-08-28

Review 2.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

Review 3.  New Treatment Options in Lupus Nephritis.

Authors:  Pauline M Montigny; Frédéric A Houssiau
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-03-17       Impact factor: 4.291

Review 4.  Induction Therapy for Lupus Nephritis: the Highlights.

Authors:  Isabelle Ayoub; Jessica Nelson; Brad H Rovin
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

5.  Rheumatic autoimmune diseases in women and midlife health.

Authors:  Wendy Marder; Évelyne Vinet; Emily C Somers
Journal:  Womens Midlife Health       Date:  2015-12-02

6.  Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.

Authors:  Jennifer C Cooper; Kelly Rouster-Stevens; Tracey B Wright; Joyce J Hsu; Marisa S Klein-Gitelman; Stacy P Ardoin; Laura E Schanberg; Hermine I Brunner; B Anne Eberhard; Linda Wagner-Weiner; Jay Mehta; Kathleen Haines; Deborah K McCurdy; Thomas A Phillips; Zhen Huang; Emily von Scheven
Journal:  Pediatr Rheumatol Online J       Date:  2018-10-22       Impact factor: 3.054

7.  Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.

Authors:  Yemil Atisha-Fregoso; Susan Malkiel; Kristina M Harris; Margie Byron; Linna Ding; Sai Kanaparthi; William T Barry; Wendy Gao; Kristin Ryker; Patti Tosta; Anca D Askanase; Susan A Boackle; W Winn Chatham; Diane L Kamen; David R Karp; Kyriakos A Kirou; S Sam Lim; Bradley Marder; Maureen McMahon; Samir V Parikh; William F Pendergraft; Amber S Podoll; Amit Saxena; David Wofsy; Betty Diamond; Dawn E Smilek; Cynthia Aranow; Maria Dall'Era
Journal:  Arthritis Rheumatol       Date:  2020-12-01       Impact factor: 15.483
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.